Life Sciences and Public Health Preparedness Federal Contracting
The Life Sciences and Public Health Preparedness practice is a multi-faceted resource for the biotechnology sector, including emerging infectious diseases, biodefense, pandemic influenza preparedness, detection and diagnostic, decision support systems for bioterrorism response, industrial biotechnology, and personalized medicine.
Our international firm helps clients exceed their business objectives by developing and executing agreements for funding for technological advancements in life sciences that allow companies to create profitable partnerships among the pharmaceutical, biotechnology, diagnostic and defense technology sectors. Equally as important, we help link the financial community with the federal government. MLA also helps develop strategies for networking with a myriad of government agencies and other policy making and funding entities, at home or abroad.
The Life Sciences and Public Health Preparedness team boasts well-respected professionals with a range of legal, political, governmental, scientific and business planning experience. We help secure government contracts and grants for technology offerings across the public health and life science sector as a result of access to political leaders, federal agency managers, scientific entrepreneurs, and company leaders who are spearheading the U.S. life sciences efforts. Members of our team work to provide strategic government affairs and business counseling, as well as due diligence reviews for investors and other entities considering joining this quickly expanding sector. MLA provides substantive value for clients regarding all public policy issues and impending legislation in the fields of biotechnology and life sciences.
The Life Sciences and Public Health Preparedness team is ready with authoritative advice on creating new markets for biotechnology companies interested in government funding from the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), the Department of Homeland Security (DHS), the Department of Defense (DOD), the Department of Energy (DOE), the Department of Agriculture (USDA), and others. In addition, our international team is skilled at dealing with various defense and health ministries throughout Europe, and non-government purchasers around the globe. Political intelligence, research and access to important decision makers is key to understanding how biotech companies can thrive. Our team also works to create profitable partnerships between companies in the pharmaceutical, biotechnology, diagnostic, detection, and information technology industries to solve global challenges.
Advisories
- August 18, 2010
- October 26, 2009
- April 29, 2009